Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Description Zetpil Suppository Advantage Zetpil delivers nutrition via the rectum with the use of suppositories that have a unique, all- natural formulated base that has revolutionized not only this mode of delivery, but also the ability to obtain nutrients in a far more efficacious method
Pioglitazone has lower PPAR agonism compared with rosiglitazone but has more profound effects on MASH, potentially mediated by the mitochondrial target of thiazolidinediones, specifically the mitochondrial pyruvate carrier
It can be self-directed or used with coaching support
- Kurt thought there was a 50% chance all GLP-1 compounding would end in the next 6 months (both 503A and 503B) - Did not mention direct communication from the FDA telling them to stop compounding GLP-1s - ProRx felt it was time to stop due to the end of the shortage in March 2025, and did not feel influenced by the April 1 FDA statement - Kurt thinks 503B production of GLP-1s are underreported and much larger than thought - 503As can't take care of the compounded GLP-1 market at their current capacity - We both have concerns about patient access without compounded GLP-1s and worry it will send more patients to the grey market for RUO injections that don't have the same level of sterility and regulation To view or add a comment, sign in Yesterday the FDA proposed removing GLP-1s from the 503B bulk list, and I spoke to Kurt Lunkwitz from ProRx to talk about changes to GLP-1 compounding
